Publication | Closed Access

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

Breast OncologyMedicinePharmacologyClinical TrialsBreast CancerPharmacotherapyCancer TreatmentOncologyPostmenopausal PatientsEndocrine-related CancerMenopause Hormone Therapy